1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
Viatris Inc.

Viatris Inc.

VTRS
Viatris Inc.US flagNASDAQ Global Select
18.22
USD
+0.78
- -
20.93BMarket Cap
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
18.03
20.66
19.97
21.59
22.28
22.22
22.3
19.87
14.8
13.42
12.85
12.35
12.21
12.72
Basic EPS, GAAP
1.63
2.49
1.8
0.94
1.3
0.69
0.03
-1.11
-1.05
1.71
0.05
-0.53
-3
-0.35
Free Cash Flow per Basic Share
2.89
2.72
4.25
3.99
3.86
4.55
3.12
1.32
2.45
2.41
2.25
1.9
1.9
1.89
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
0.33
0.48
0.48
0.48
0.48
0.48
Book Value per Share
7.92
8.68
19.9
20.77
25.39
23.59
23.02
19.02
16.94
17.36
17.05
15.61
12.78
12.34
Tangible Book Value per Share
-10.54
-8.37
-5.78
-23.47
-23.17
-21.8
-18.13
-15.81
-14.68
-9.85
-7.15
-6.34
-6.21
-5.26
Basic Weighted Avg Shares
383
374
472
513
534
514
516
601
1,209
1,212
1,200
1,193
1,171
1,159
Sales/Revenue/Turnover
6,909
7,720
9,429
11,077
11,908
11,434
11,500
11,946
17,886
16,263
15,427
14,739
14,300
14,737
Operating Margin (%)
16.22
17.11
14.46
12.38
11.96
7.49
6.04
-0.51
2.04
10.18
10.13
4.82
1.77
0.89
Depreciation Expense
516
567
1,032
1,523
1,806
2,110
2,019
2,216
4,506
3,028
2,740
2,893
2,798
2,804
Net Income, GAAP
624
929
848
480
696
352
17
-670
-1,269
2,079
55
-634
-3,515
-411
Effective Tax Rate (%)
16.16
4.25
7.4
- -
22.92
- -
89.12
- -
- -
26.11
73.04
- -
- -
- -
Profit Margin (%)
9.03
12.04
8.99
4.33
5.84
3.08
0.15
-5.61
-7.1
12.78
0.35
-4.3
-24.58
-2.79
Working Capital
1,507
1,137
2,350
2,482
828
1,780
1,188
2,305
1,018
3,889
5,199
3,741
2,695
3,710
LT Debt
7,586
5,700
6,296
15,203
12,865
13,161
11,390
22,659
19,918
18,197
16,354
14,218
12,659
11,772
Total Equity
2,960
3,276
9,766
11,118
13,308
12,167
11,884
22,954
20,493
21,072
20,467
18,636
14,711
14,260
Return on Invested Capital (%)
9.32
11
9.24
- -
4.32
- -
0.3
- -
- -
2.89
1.06
- -
- -
- -
Return on Capital (%)
8.8
10.93
8.03
- -
4.05
- -
0.29
- -
- -
5.96
0.53
- -
- -
- -
Return on Common Equity (%)
19.86
29.99
13.02
4.6
5.7
2.77
0.14
-3.85
-5.84
10
0.26
-3.24
-21.08
-2.75

Capital Structure

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
2,039
2,029
1,854
LT Borrowings
12,481
12,414
11,612
LT Finance Leases
178
167
160
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,151
1,164
1,155
Market Capitalization
14,333
15,731
18,345

Working Capital

FRC

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
9,789
10,917
10,056
Cash, Cash Equivalents & STI
1,513
2,400
1,510
Accounts Receivable, Net
2,578
2,577
2,581
Inventories
3,999
3,927
3,933
Total Current Liabilities
7,094
6,810
6,346
Payables & Accruals
4,065
3,843
3,626
ST Debt
2,039
2,029
1,854
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.5%
-8.15%
-21.06%
Free Cash Flow
18.11%
49.37%
-1.77%
Net Income, GAAP
-530.73%
-215.38%
454.23%
Sales/Revenue/Turnover
5.35%
5.61%
-2.98%
Total Cash Common Dividend
- -
- -
-2.37%

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
3,663
3,797
3,751
3,528
14,739
2025
3,254
3,582
3,760
3,704
14,300
2026
3,517
3,757
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.1
-0.27
0.08
-0.43
-0.53
2025
-2.55
- -
-0.11
-0.3
-3
2026
0.15
-0.1
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.12
0.12
0.12
0.12
0.48
2025
0.12
0.12
0.12
0.12
0.48
2026
0.12
0.12
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Scott Andrew Smith
Full Time Employees
30,000
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Address
Robert J. Coury Global Center Canonsburg PA United States of America 15317
IPO Date
Mar 17, 1980
CIK
0001792044
Website
viatris.com
Similar Companies
Nutra Pharma Corp. (NPHC)
BellRock Brands Inc. (DXBRF)
Wakamoto Pharmaceutical Co.,Ltd. (4512.T)
Zomedica Corp. (ZOM)
Canada House Cannabis Group Inc. (CHV.CN)
Tianjin Pharmaceutical Da Ren Tang Group Corporation Limited (600329.SS)
Business
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company that develops, manufactures and markets a broad portfolio of branded and generic pharmaceuticals, biosimilars and complex generics; key brands include Lipitor, Norvasc, Viagra, Lyrica, Xanax, Creon, Celebrex, Effexor, Zoloft and EpiPen auto-injectors; generics and branded generics span therapeutic areas such as cardiovascular, central nervous system, infectious diseases, oncology, immunology, women's health, diabetes, gastroenterology, respiratory, allergy and dermatology; additional offerings encompass complex generics like Breyna (generic Symbicort), recent launches including Iron Sucrose Injection USP for iron deficiency anemia and Ryzumvi (phentolamine ophthalmic solution) for mydriasis; the company operates in developed markets, emerging markets, JANZ (Japan, Australia, New Zealand) and Greater China, supplying medicines to approximately 1 billion patients annually through global manufacturing and supply chain infrastructure. Headquartered in Canonsburg, Pennsylvania, Viatris was formed in 2020 through the merger of Mylan N.V. and Pfizer's Upjohn division. Recent developments include the completion of the acquisition of Aculys Pharma Inc. in 2025, securing exclusive rights to pitolisant for narcolepsy and obstructive sleep apnea in Japan and Spydia Nasal Spray for status epilepticus in Japan and certain Asia-Pacific markets; submission of a New Drug Application to the U.S. FDA for a low-dose estrogen weekly patch, with anticipated approval by mid-2026; prior divestitures in 2023-2024 of its OTC business to Cooper Consumer Health, women's healthcare business and India API operations for approximately $3.6 billion; an ongoing enterprise-wide strategic review initiated in February 2025 to identify operating efficiencies in commercial, R&D, supply chain and corporate functions; and a December 2024 U.S. FDA warning letter and import alert on its Indore, India facility impacting 11 products, prompting corrective actions.

Company News

Company News APIChatGPT

  • businesswire.com

    Pacira BioSciences Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Pacira BioSciences, Inc. - PCRX

  • zacks.com

    Viatris to Buy Pacira for $1.65B to Expand Non-Opioid Pain Portfolio

  • newsfilecorp.com

    SHAREHOLDER NOTICE: Brodsky & Smith Announces an Investigation of Pacira BioSciences, Inc. (PCRX)

  • fool.com

    Why Pacira BioSciences Skyrocketed Today

  • wsj.com

    Viatris to Buy Pacira BioSciences for $1.65 Billion

  • prnewswire.com

    Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies

  • zacks.com

    VTRS vs. AVTR: Which Stock Is the Better Value Option?

  • zacks.com

    Should Value Investors Buy Viatris (VTRS) Stock?

  • zacks.com

    Viatris (VTRS) is a Top-Ranked Momentum Stock: Should You Buy?

  • prnewswire.com

    Viatris to Report Third-Quarter 2026 Financial Results on November 5, 2026

  • zacks.com

    Why Viatris (VTRS) is a Top Value Stock for the Long-Term

  • gurufocus.com

    Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year

  • prnewswire.com

    Viatris Recognized by Forbes as One of the World's Best Employers for the Sixth Consecutive Year

  • benzinga.com

    Wall Street's Most Accurate Analysts Weigh In On 3 Health Care Stocks Delivering High-Dividend Yields

  • prnewswire.com

    Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome

  • seekingalpha.com

    Viatris: Strong Cash Generation And Pipeline Progress Keep The Re-Rating Story Alive

  • zacks.com

    Viatris (VTRS) is a Top-Ranked Value Stock: Should You Buy?

  • proactiveinvestors.co.uk

    Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris

  • zacks.com

    3 Generic Drug Stocks to Watch Amid Improving Industry Trends

  • zacks.com

    Here's Why Viatris (VTRS) is a Strong Value Stock